Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Bristol's Strong Efficacy in Lung Cancer Study Supports Our Above-Consensus Projections for Opdivo

    Commentary

    Fri, 17 Apr 2015

    strong results from Checkmate 057 likely move Opdivo slightly ahead of immuno-oncology drugs from Merck, Roche, and AstraZeneca in the most important indication of nonsquamous non-small cell lung cancer, which represent close to half of our market

  2. BRIEF- AstraZeneca lung cancer drug delays disease by more than a year

    Headlines

    Fri, 17 Apr 2015

    * Astrazeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291

  3. AstraZeneca lung cancer drug delays disease by more than a year

    Headlines

    Fri, 17 Apr 2015

    LONDON, April 17 (Reuters) - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

  4. BRIEF- Astrazeneca gets orphan drug status for uveal melanoma treatment

    Headlines

    Fri, 17 Apr 2015

    * U.S. FDA has granted orphan drug designation for mek inhibitor selumetinib, for treatment of uveal melanoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

  5. BRIEF- Astrazeneca , Immunocore tie-up to conduct immuno-oncology trials

    Headlines

    Thu, 16 Apr 2015

    * Medimmune unit entered into collaboration to conduct clinical trials in immuno-oncology with privately-held immunocore limited

  6. AstraZeneca science is on the move, one year on from Pfizer bid

    Headlines

    Wed, 15 Apr 2015

    * New drugs make progress, high hopes in lung cancer treatment

  7. Britain's FTSE sets fresh record high; Dixons, Next rally

    Headlines

    Wed, 15 Apr 2015

    * AstraZeneca boosted as medicine gains orphan status in U.S.

  8. AstraZeneca immune system drug wins orphan status in rare cancer

    Headlines

    Wed, 15 Apr 2015

    LONDON, April 15 (Reuters) - An experimental medicine from AstraZeneca that helps the immune system fight tumours has won "orphan" drug status in the United States for treating malignant mesothelioma, a rare type of cancer.

  9. UPDATE 3-FDA panel backs safety updates for AstraZeneca , Takeda drugs

    Headlines

    Tue, 14 Apr 2015

    WASHINGTON, April 14 (Reuters) - AstraZeneca Plc 's diabetes drug Onglyza and Takeda Pharmaceutical Co.'s rival product Nesina should carry information about the risk of heart failure, an advisory...

  10. U.S. FDA panel favors new safety information on AstraZeneca's Onglyza

    Headlines

    Tue, 14 Apr 2015

    WASHINGTON, April 14 (Reuters) - AstraZeneca Plc 's diabetes drug Onglyza should include new safety information about the risk of heart failure, an advisory panel to the U.S. Food and Drug...

« Prev12345Next »
Content Partners